Bayer AG has been boosted by positive topline data on finerenone, one of the lead assets in its pipeline, which showed that the drug lowered the risk of renal and cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes.
The German group has given the first insight into the 5,700-patient Phase III study FIDELIO-DKD which revealed that finerenone significantly reduced the combined primary endpoint of CKD progression, kidney failure or kidney death versus placebo when added to standard of care
